FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891096435> ?p ?o ?g. }

• W2891096435 endingPage "1110" @default.
• W2891096435 startingPage "1095" @default.
• W2891096435 abstract "Bone loss is common in advanced cirrhosis, although the precise mechanisms underlying bone loss in cirrhosis are unknown. We studied the profile and functionality of bone‐forming cells and bone‐building proteins in bone marrow (BM) of individuals with cirrhosis (n = 61) and individuals without cirrhosis as normal controls (n = 50). We also performed dual energy X‐ray absorptiometry for clinical correlation. BM mesenchymal cells (MSCs) were analyzed for colony‐forming units‐fibroblasts and their osteogenic (fibronectin‐1 [ FN1 ] , insulin‐like growth factor binding protein 3 [ IGFBP3 ] , collagen type 1 alpha 1 chain [ COL1A1 ] , runt‐related transcription factor 2 [ RUNX2 ], and alkaline phosphatase, liver [ ALPL ]) and adipogenic ( adiponectin, C1Q, and collagen domain containing [ ADIPOQ ] , peroxisome proliferator‐activated receptor gamma [ PPARγ ] , and fatty acid binding protein 4 [ FABP4 ]) potentials. Colony‐forming units‐fibroblasts were lower in patients with cirrhosis ( P = 0.002) than in controls. Cirrhotic BM‐MSCs showed >2‐fold decrease in osteogenic markers. Compared to controls, patients with cirrhosis showed fewer osteocytes ( P = 0.05), osteoblasts, chondroblasts, osteocalcin‐positive (osteocalcin+) area, clusters of differentiation (CD)169+ macrophages ( P < 0.001, each), and nestin+ MSCs ( P = 0.001); this was more apparent in Child‐Turcotte‐Pugh (CTP) class C than A ( P < 0.001). Multivariate logistic regression showed low nestin+ MSCs ( P = 0.004) as a predictor of bone loss. Bone‐resolving osteoclasts were comparable among CTP groups, but >2‐fold decreased anti‐osteoclastic and increased pro‐osteoclastic factors were noted in patients with CTP C compared to CTP A. Bone‐building proteins (osteocalcin [ P = 0.008], osteonectin [ P < 0.001], and bone morphogenic protein 2 [ P = 0.001]) were decreased while anti‐bone repair factors (fibroblast growth factor 23 [ P = 0.015] and dipeptidyl peptidase 4 [ P < 0.001]) were increased in BM and peripheral blood; this was more apparent in advanced cirrhosis. The dual energy X‐ray absorptiometry scan T score significantly correlated with the population of osteoblasts, osteocytes, MSCs, and CD169+ macrophages. Conclusion: Osteoprogenitor cells are substantially reduced in patients with cirrhosis and more so in advanced disease. Additionally, increased anti‐bone repair proteins enhance the ineffective bone repair and development of osteoporosis in cirrhosis. Hepatology Communications 2018;0:0‐0)" @default.
• W2891096435 created "2018-09-27" @default.
• W2891096435 creator A5002695856 @default.
• W2891096435 creator A5004402988 @default.
• W2891096435 creator A5015911393 @default.
• W2891096435 creator A5018070452 @default.
• W2891096435 creator A5026249679 @default.
• W2891096435 creator A5026415059 @default.
• W2891096435 creator A5049994962 @default.
• W2891096435 creator A5053632477 @default.
• W2891096435 creator A5056571923 @default.
• W2891096435 creator A5058953140 @default.
• W2891096435 creator A5068701943 @default.
• W2891096435 creator A5088960523 @default.
• W2891096435 creator A5089388763 @default.
• W2891096435 creator A5089733517 @default.
• W2891096435 date "2018-09-01" @default.
• W2891096435 modified "2023-10-11" @default.
• W2891096435 title "Suboptimal Level of Bone‐Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy" @default.
• W2891096435 cites W1967502057 @default.
• W2891096435 cites W1980740451 @default.
• W2891096435 cites W1992267135 @default.
• W2891096435 cites W1997178163 @default.
• W2891096435 cites W2006041438 @default.
• W2891096435 cites W2015050458 @default.
• W2891096435 cites W2033640443 @default.
• W2891096435 cites W2047841709 @default.
• W2891096435 cites W2050382605 @default.
• W2891096435 cites W2056510698 @default.
• W2891096435 cites W2059823035 @default.
• W2891096435 cites W2063276429 @default.
• W2891096435 cites W2075853089 @default.
• W2891096435 cites W2077703010 @default.
• W2891096435 cites W2091600198 @default.
• W2891096435 cites W2092045620 @default.
• W2891096435 cites W2129663763 @default.
• W2891096435 cites W2129875047 @default.
• W2891096435 cites W2134267673 @default.
• W2891096435 cites W2135944921 @default.
• W2891096435 cites W2147758984 @default.
• W2891096435 cites W2158245729 @default.
• W2891096435 cites W2167207642 @default.
• W2891096435 cites W2173021891 @default.
• W2891096435 cites W2217775969 @default.
• W2891096435 cites W2266589761 @default.
• W2891096435 cites W2269475172 @default.
• W2891096435 cites W2330722106 @default.
• W2891096435 cites W2331329165 @default.
• W2891096435 cites W2497393003 @default.
• W2891096435 cites W2514700620 @default.
• W2891096435 cites W2514899465 @default.
• W2891096435 cites W2583356399 @default.
• W2891096435 cites W2595342131 @default.
• W2891096435 cites W3190705041 @default.
• W2891096435 cites W348416162 @default.
• W2891096435 cites W64900560 @default.
• W2891096435 doi "https://doi.org/10.1002/hep4.1234" @default.
• W2891096435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6128237" @default.
• W2891096435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30202823" @default.
• W2891096435 hasPublicationYear "2018" @default.
• W2891096435 type Work @default.
• W2891096435 sameAs 2891096435 @default.
• W2891096435 citedByCount "12" @default.
• W2891096435 countsByYear W28910964352019 @default.
• W2891096435 countsByYear W28910964352020 @default.
• W2891096435 countsByYear W28910964352021 @default.
• W2891096435 countsByYear W28910964352022 @default.
• W2891096435 countsByYear W28910964352023 @default.
• W2891096435 crossrefType "journal-article" @default.
• W2891096435 hasAuthorship W2891096435A5002695856 @default.
• W2891096435 hasAuthorship W2891096435A5004402988 @default.
• W2891096435 hasAuthorship W2891096435A5015911393 @default.
• W2891096435 hasAuthorship W2891096435A5018070452 @default.
• W2891096435 hasAuthorship W2891096435A5026249679 @default.
• W2891096435 hasAuthorship W2891096435A5026415059 @default.
• W2891096435 hasAuthorship W2891096435A5049994962 @default.
• W2891096435 hasAuthorship W2891096435A5053632477 @default.
• W2891096435 hasAuthorship W2891096435A5056571923 @default.
• W2891096435 hasAuthorship W2891096435A5058953140 @default.
• W2891096435 hasAuthorship W2891096435A5068701943 @default.
• W2891096435 hasAuthorship W2891096435A5088960523 @default.
• W2891096435 hasAuthorship W2891096435A5089388763 @default.
• W2891096435 hasAuthorship W2891096435A5089733517 @default.
• W2891096435 hasBestOaLocation W28910964351 @default.
• W2891096435 hasConcept C126322002 @default.
• W2891096435 hasConcept C131075544 @default.
• W2891096435 hasConcept C134018914 @default.
• W2891096435 hasConcept C160160445 @default.
• W2891096435 hasConcept C181199279 @default.
• W2891096435 hasConcept C185592680 @default.
• W2891096435 hasConcept C2777214474 @default.
• W2891096435 hasConcept C2780007613 @default.
• W2891096435 hasConcept C55493867 @default.
• W2891096435 hasConcept C71924100 @default.
• W2891096435 hasConceptScore W2891096435C126322002 @default.
• W2891096435 hasConceptScore W2891096435C131075544 @default.
• W2891096435 hasConceptScore W2891096435C134018914 @default.
• W2891096435 hasConceptScore W2891096435C160160445 @default.

• next